A randomised clinical trial investigating the effect of pertuzumab versus placebo in people with operable HER2-positive eBC
| Studied treatment | Six to eight cycles of chemotherapy (anthracycline or non-anthracycline-containing regimen) with Perjeta and Herceptin, followed by Perjeta and Herceptin every three weeks for a total of one year (52 weeks) of treatment | 
| Control treatment | Six to eight cycles of chemotherapy (anthracycline or non-anthracycline-containing regimen) with placebo and Herceptin, followed by placebo and Herceptin every three weeks for a total of one year (52 weeks) of treatment | 
| Patients | people with operable HER2-positive eBC | 
| Size | 4805 | 
| Blindness | double-blind | Inclusion period | |
| Follow-up duration | Centers | ||
| Lost to FU | geographical localisation | ||
| Primary endpoint | iDFS | Design | Parallel groups | 
Appears in following systematic reviews: